Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 04, 2007. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, and Connected Persons in the company's Ordinary shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than corporate financial performance.
Material Changes and Transactions
The filing details sales of shares by specific individuals to meet tax liabilities following the vesting of Share Value Plan awards on December 3, 2007:
- Ordinary Shares (GBP 12.84/share):
- Dr. M M Slaoui: Sold 541 shares; retained 2,809.
- Mr. D Learmouth: Sold 1,296 shares; retained 1,864.
- Mrs. Claudine Bruck Slaoui (spouse of Dr. Slaoui): Sold 417 shares; retained 893.
- American Depositary Shares (USD 52.68/ADS):
- Mr. W Louv: Sold 500 ADSs; retained 980.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total volume of shares sold by management to meet tax obligations versus shares retained.
- Confirm the transaction price of GBP 12.84 per Ordinary share and USD 52.68 per ADS against market prices on December 3, 2007.
- Review the specific Share Value Plan award terms that triggered these vesting events.